Takayama, Koichi

Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis

Takayama, K., & Kilburn, J. O. (1989) · Antimicrobial Agents and Chemotherapy

Tuberculosis Research and EpidemiologyBacterial Genetics and Biotechnology

Cited by 369

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer

Nutrition and Health in AgingRegulation of Appetite and Obesity

Cited by 239

Interleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas

Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer

Occupational and environmental lung diseasesCytokine Signaling Pathways and Interactions

Cited by 115

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Shiraishi, Y., Kishimoto, J., Sugawara, S., Mizutani, H., Daga, H., Azuma, K., Matsumoto, H., Hataji, O., Nishino, K., Mori, M., et al. (2024) · JAMA Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 54

Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan

Uchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., & Nakanishi, Y. (2008) · Cancer Gene Therapy

Toxin Mechanisms and ImmunotoxinsBacterial Cancer Therapy

Cited by 21

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 20

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

Katayama, Y., Yamada, T., Tanimura, K., Yoshimura, A., Takeda, T., Chihara, Y., Tamiya, N., Kaneko, Y., Uchino, J., & Takayama, K. (2019) · Thoracic Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 20

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer

Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 15